ANAPTYSBIO, INC — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
AnaptysBio reported Jemperli global net sales of $644M (£480M) for H1 2026, up 34% YoY, generating $53M collaboration revenue. Positive interim AZUR-1 trial data supports February 2027 FDA PDUFA decision for monotherapy in dMMR/MSI-H rectal cancer, with potential expedited review via National Priority Voucher. Separately, Delaware Chancery Court trial (July 2026) against GSK and Tesaro concluded; post-trial hearing scheduled October 20, 2026, with judgment anticipated Q4 2026 or Q1 2027; Anaptys seeks reversion of Jemperli rights.
Why this rating
Strong royalty growth and FDA near-term catalyst are material; litigation outcome highly uncertain but could be transformational (reversion vs. status quo). Sized ~15% of market cap; significant but not yet defining.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.